AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03649893 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Office
Description: Active Office intervention includes sit-to-stand desk, bike desk, seddle chair, and active breaks.
Study NCT02235025 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Cardio-pulmonary exercise testing
Study NCT00532532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tolperisone HCl
Description: Low dose AV650 three times a day orally for 5 weeks; followed by optional continuation on either low dose or high dose AV650, as tolerated, for 24 weeks
Study NCT00532532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tolperisone HCl
Description: High dose AV650 three times a day orally for 5 weeks; followed by optional continuation on either low dose or high dose AV650, as tolerated, for 24 weeks
Study NCT00532532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tolperisone HCl
Description: Placebo three times a day orally for 5 weeks; followed by optional continuation on either low dose or high dose AV650, as tolerated, for 24 weeks
Study NCT02420262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/liraglutide
Description: Once daily injected s.c./subcutaneously (under the skin) in combination with metformin.
Study NCT02420262 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine
Description: Once daily injected s.c./subcutaneously (under the skin) in combination with metformin.
Study NCT02420262 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin aspart
Description: Injected s.c./subcutaneously (under the skin) before each main meal.
Study NCT05455151 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conservative therapy
Description: Conservative therapy to which the patients were subjected was the effect of an electrical impulse
Study NCT05455151 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRP injection
Description: This intervention consisted of injecting platelet-rich plasma (PRP) into the endometrium
Study NCT05455151 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Injection of PRP after conservative therapy
Description: This intervention consisted of conducting conservative therapy with an electrical impulse and then injecting PRP inside the endometrium
Study NCT05455151 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Injection of PRP with endometrial cells
Description: This intervention consisted of injecting endometrial cells suspended in prp
Study NCT03404388 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Balance Training
Description: 4 days of a challenging balance training task
Study NCT03210051 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning
Description: RIC is a physical strategy performed by an electric autocontrol device with cuffs placed on bilateral arms and inflated to 200 mmHg for 5-min followed by deflation for 5-min, the procedures is performed repeatedly for 5 times.
Study NCT03210051 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endovascular treatment
Description: Endovascular treatment include strategies that used to recanalize the occluded artery. Strategies often used include thrombectomy, intra-arterial thrombolysis, stenting and balloon angiography.
Study NCT04360369 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IOP with Goldmann Applanation Tonometer
Description: Measurement of intraocular pressure (IOP) with Goldmann Applanation Tonometer. Measurement will be used to categorize each subject as having Low IOP (7 to 16 mmHg), Medium IOP (>16 to \<23 mmHg), or High IOP (>23 mmHg).
Study NCT04360369 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IOP with comparator ORA G3 and ic100 tonometers
Description: Measurement of IOP with Ocular Response Analyzer G3 and ic100 tonometers.
Study NCT04360369 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IOP with Tono-Vera Tonometer
Description: Measurement of IOP with Tono-Vera Tonometer
Study NCT04058197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferoxamine Product
Description: Deferoxamine Intradermal Delivery Patch
Study NCT04058197 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Patch
Study NCT02716779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon (PEG-IFN) alfa-2a
Description: Pegylated interferon (PEG-IFN) alfa-2a (40 kilodalton \[KD\]) 180 microgram (mcg) subcutaneously (SC) weekly, for 6 weeks during monotherapy and/or 12 weeks during combination therapy.
Study NCT02716779 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pegylated Interferon (PEG-IFN) alfa-2a
Description: Pegylated interferon (PEG-IFN) alfa-2a (40 kilodalton \[KD\]) 180 microgram (mcg) subcutaneously (SC) weekly, for 6 weeks during monotherapy and/or 12 weeks during combination therapy.
Study NCT02716779 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ribavirin matching placebo orally (PO) twice daily for 6 weeks.
Study NCT02716779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin, 1000 mg orally (PO) (400 mg in the morning \[=2 tablets\] and 600 mg in the evening \[=3 tablets\]) in participants with a body weight less than 75 kilogram (kg) or 1200 mg PO (600 mg at each time =3 tablets, in the morning and evening, respectively) in participants with a body weight greater than or equal to 75 kg, PO daily for 6 weeks during monotherapy and/or 12 weeks during combination therapy.
Study NCT02716779 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ribavirin
Description: Ribavirin, 1000 mg orally (PO) (400 mg in the morning \[=2 tablets\] and 600 mg in the evening \[=3 tablets\]) in participants with a body weight less than 75 kilogram (kg) or 1200 mg PO (600 mg at each time =3 tablets, in the morning and evening, respectively) in participants with a body weight greater than or equal to 75 kg, PO daily for 6 weeks during monotherapy and/or 12 weeks during combination therapy.
Study NCT03488797 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised web- and home-based exercise intervention
Description: * The intervention group gets access to a training platform. Every week, 3 training videos of 20 minutes each will be released on that platform with the aim to perform those during the ongoing week.~* Each exercise session is arranged in a video session with child friendly instructions and executions for the different exercises. The videos serve as a virtual training partner and exercise will be performed simultaneously while watching the video~* The overall training volume is 72 session calculated from 3 sessions per week over a duration of 24 weeks (6 month)
Study NCT00004067 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: herceptin
Description: 4 mg/kg loading dose then 2 mg/kg weekly for 1 year.
Study NCT00004067 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adriamycin
Description: 60 mg/m2 IV push every 21 days for 4 cycles.
Study NCT00004067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adriamycin
Description: 60 mg/m2 IV push every 21 days for 4 cycles.
Study NCT00004067 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: 600 mg/m2 IV every 21 days for 4 cycles
Study NCT00004067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 600 mg/m2 IV every 21 days for 4 cycles
Study NCT00004067 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: taxol
Description: 175 mg/m2 IV every 21 days for 4 cycles
Study NCT00004067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: taxol
Description: 175 mg/m2 IV every 21 days for 4 cycles
Study NCT00320788 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aflibercept injection (VEGF Trap-Eye, BAY86-5321)
Description: Participants received 0.5 mg of aflibercept injection (VEGF Trap-Eye, BAY86-5321) at 4 week intervals through Week 12
Study NCT00320788 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aflibercept injection (VEGF Trap-Eye, BAY86-5321)
Description: Participants received 0.5 mg of aflibercept injection (VEGF Trap-Eye, BAY86-5321) at 12 week intervals through Week 12.
Study NCT00320788 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aflibercept injection (VEGF Trap-Eye, BAY86-5321)
Description: Participants received 2.0 mg of aflibercept injection (VEGF Trap-Eye, BAY86-5321) at 4 week intervals through Week 12
Study NCT00320788 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aflibercept injection (VEGF Trap-Eye, BAY86-5321)
Description: Participants received 2.0 mg of aflibercept injection (VEGF Trap-Eye, BAY86-5321) at 12 week intervals through Week 12.
Study NCT00320788 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aflibercept injection (VEGF Trap-Eye, BAY86-5321)
Description: Participants received 4.0 mg of aflibercept injection (VEGF Trap-Eye, BAY86-5321) at 12 week intervals through Week 12.
Study NCT04396132 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Subjective Visual Vertical with Virtual SVV instrument
Description: The deviation angle will be measured with 15, 30 and 45-degree head tilt to the left and right side while they are standing
Study NCT05986292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3016859 ISA
Description: Administered intravenously (IV)
Study NCT00959283 — intervention group
Intervention type: OTHER
Intervention: Diagnostic Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00959283 — intervention group
Intervention type: OTHER
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT05986292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3556050 ISA
Description: Administered orally
Study NCT05986292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3526318 ISA
Description: Administered orally
Study NCT05986292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3857210 ISA
Description: Administered orally
Study NCT05986292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral
Description: Placebo administered orally
Study NCT05986292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo administered IV
Study NCT03311841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam oral solution
Description: Midazolam hydrochloride 10 μg (1 mL of 10 μg/mL oral solution), administered orally as part of a microdose cocktail
Study NCT03311841 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam oral solution
Description: Midazolam hydrochloride 10 μg (1 mL of 10 μg/mL oral solution), administered orally as part of a microdose cocktail
Study NCT03311841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran and pitavastatin oral solution
Description: 375/10 μg dabigatran etexilate and pitavastatin (1 mL of 375/10 μg/mL oral solution), administered orally as part of a microdose cocktail
Study NCT03311841 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dabigatran and pitavastatin oral solution
Description: 375/10 μg dabigatran etexilate and pitavastatin (1 mL of 375/10 μg/mL oral solution), administered orally as part of a microdose cocktail
Study NCT03311841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin and rosuvastatin oral solution
Description: 100/50 μg atorvastatin and rosuvastatin (2 mL of 50/25 μg/mL oral solution), administered orally as part of a microdose cocktail
Study NCT03311841 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin and rosuvastatin oral solution
Description: 100/50 μg atorvastatin and rosuvastatin (2 mL of 50/25 μg/mL oral solution), administered orally as part of a microdose cocktail
Study NCT03311841 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampin
Description: Rifampin 600 mg single dose (two 300 mg capsules) administered orally
Study NCT04442022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor (combination therapy)
Description: Dose: 40 mg on Days 1 and 8 of each 21-day cycle for up to 6 cycles; Route of administration: oral
Study NCT04442022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor (combination therapy)
Description: Dose: 60 mg on Days 1 and 8 of each 21-day cycle for up to 6 cycles; Route of administration: oral
Study NCT04442022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor (combination therapy)
Description: Dose: Selected dose of selinexor (from Phase 2) on Days 1 and 8 of each 21-day cycle for up to 6 cycles; Route of administration: oral
Study NCT04442022 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching for Selinexor (combination therapy)
Description: Dose: Placebo matching for selected dose of selinexor (from Phase 2) on Days 1 and 8 of each 21-day cycle for up to 6 cycles; Route of administration: oral
Study NCT04442022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab (combination therapy)
Description: Dose: 375 milligram per meter square (mg/m\^2) on Day 1; Route of administration: intravenous (IV)
Study NCT04442022 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab (combination therapy)
Description: Dose: 375 mg/m\^2 on Day 1; Route of administration: IV
Study NCT04442022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab (combination therapy)
Description: Dose: 375 mg/m\^2 on Day 1; Route of administration: IV
Study NCT04442022 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rituximab (combination therapy)
Description: Dose: 375 mg/m\^2 on Day 1; Route of administration: IV
Study NCT04442022 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine (combination therapy)
Description: Dose: 1000 mg/m\^2 on Days 1 and 8; Route of administration: IV
Study NCT04442022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine (combination therapy)
Description: Dose: 1000 mg/m\^2 on Days 1 and 8; Route of administration: IV
Study NCT04442022 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemcitabine (combination therapy)
Description: Dose: 1000 mg/m\^2 on Days 1 and 8; Route of administration: IV
Study NCT04442022 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone (combination therapy)
Description: Dose: 40 mg (20 mg if patient is more than 70 years old) on Days 1, 2, 3, and 4; Route of administration: oral or IV
Study NCT04442022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone (combination therapy)
Description: Dose: 40 mg (20 mg if patient is more than 70 years old) on Days 1, 2, 3, and 4; Route of administration: oral or IV
Study NCT04442022 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone (combination therapy)
Description: Dose: 40 mg (20 mg if patient is more than 70 years old) on Days 1, 2, 3, and 4; Route of administration: oral or IV
Study NCT04442022 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin (combination therapy)
Description: Dose: 75 mg/m\^2 on Day 1; Route of administration: IV
Study NCT04442022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin (combination therapy)
Description: Dose: 75 mg/m\^2 on Day 1; Route of administration: IV
Study NCT04442022 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin (combination therapy)
Description: Dose: 75 mg/m\^2 on Day 1; Route of administration: IV
Study NCT04442022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor (continuous therapy)
Description: Dose: 60 mg QW for each 28-day cycle until PD; Route of administration: oral
Study NCT04442022 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching for Selinexor (continuous therapy)
Description: Dose: Placebo matching for 60 mg selinexor QW for each 28-day cycle until PD; Route of administration: oral
Study NCT04442022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching for Selinexor (continuous therapy)
Description: Dose: Placebo matching for 60 mg selinexor QW for each 28-day cycle until PD; Route of administration: oral
Study NCT02156739 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced Magnetic Resonance Imaging
Description: Undergo contrast-enhanced MRI
Study NCT02156739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadobutrol
Description: Given IV
Study NCT02156739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadoxetate Disodium
Description: Given IV
Study NCT02316002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Study NCT02683447 — intervention group
Intervention type: OTHER
Intervention: CRM Simulation
Description: Each participant will manage a PEA arrest scenario (pre-test) and then be debriefed on their CRM skills by a trained facilitator for 20 minutes. They will then manage another crisis scenario (PEA arrest with a different inciting event) as an immediate post-test. Three months afterwards participants will return to manage a third PEA arrest scenario, which will serve as a retention post-test.
Study NCT01886872 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bendamustine Hydrochloride
Description: Given IV
Study NCT01886872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO
Study NCT01886872 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01886872 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01886872 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT01886872 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT01886872 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Given IV
Study NCT01886872 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study NCT01565109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel - Cisplatine - 5FU
Description: 2 cycles of Docetaxel - Cisplatine - 5 FU
Study NCT01565109 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation of 45 Grays on 5 weeks
Description: Radiochemotherapy with Oxaliplatine (J1, J15 et J29) - 5FU on 5 weeks
Study NCT03311841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Rifampin 600 mg single dose (two 300 mg capsules) administered orally
Study NCT02480881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-663068
Description: Investigational product
Study NCT02480881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Contraceptive
Description: Subject's existing combination OC tablet containing EE and progestin
Study NCT02480881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loestrin 1.5/30
Description: OC containing EE and norethindrone acetate (NEA)
Study NCT01941784 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational intervention
Description: Undergo health education program
Study NCT01941784 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: counseling intervention
Description: Undergo health education program
Study NCT01941784 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: telephone-based intervention
Description: Receive follow-up phone calls
Study NCT01941784 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT01941784 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT00640419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-089
Description: Subjects will take 10 mg capsules and/or 40 mg tablets (actual dose based on weight) once daily for 6 weeks.
Study NCT00640419 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Subjects will take placebo capsules and/or tablets (number of capsules or tablets will be based upon weight) once daily for duration of the study.
Study NCT00725907 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PGRF
Description: injection of 6cc into injured area
Study NCT00725907 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo saline
Description: injection of 6cc into injured area
Study NCT01909141 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: induction of ovulation using letrozole-pioglitazone-metformin
Description: induction of ovulation will be done for arm 1 for 3 consecutive cycles unless pregnancy occured.
Study NCT01909141 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: induction of ovulation using clomiphene citrate-pioglitazone-metformin
Description: induction of ovulation for arm 2 will be done in 3 consecutive cycles unless pregnancy occured.